T3 Advisors, A Savills Company
The COVID-19 pandemic has brought the life sciences sector to the fore. The development of vaccines in record time has made such companies as Novovax, BioNTech and Sinovac household names.
Though attention has grown in recent months, the sector has been driving innovation and discovery for decades. Record funding has flowed into the sector, with venture capital (VC) into life sciences rising by 69% last year.
With sector growth and investor interest challenging available inventory and driving up values, how can biotech, pharma, and other life science tenants meet their needs to swiftly and cost-effectively establish or scale lab space?
On June 11, T3 Advisors, one of the most trusted real estate and workplace advisory firms to companies operating within the life sciences sector, joined global real estate advisory firm Savills, to become T3 Advisors, A Savills Company. T3’s expertise combines with Savills’ footprint to meet the life sciences sector’s growing demand for specialized real estate services and facilities across the country and around the world.
T3’s innovative approach to serving occupiers in the life sciences community not only resolves complex operational needs, but also creates location and occupancy strategies that build sustainable company cultures — and which attract and retain the best specialized talent in the industry.
Download T3’s Guide to Life Sciences Facility Strategy and review:
- how to locate, build and scale lab facilities that promote innovation, accuracy and cost-containment, while meeting regulatory requirements;
- how to develop strategies that align long-term science and business goals; and
- how to manage expectations demanded by a complex planning process, yet meet time-sensitive targets for business operations.
